BRIUMVI vs GILENYA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. BRIUMVI and GILENYA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BRIUMVI	GILENYA
Rating	New	70/100
Pharmacy pays	—	~$126.02 /30
Type	RX	RX
Active ingredient	UBLITUXIMAB-XIIY	FINGOLIMOD HYDROCHLORIDE
Manufacturer	Tg Therapeutics, Inc	Novartis
Dosage forms	Injectable	Capsule
Drug class	—	Sphingosine 1-Phosphate Receptor Modulator
Boxed warning	None	None
Half-life	—	about 6 to 9 days (average apparent terminal half-life)
Treats	Demyelinating Diseases, Chronic Progressive Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis

briumvi gilenya

Rating

New

70/100

Pharmacy pays

—

~$126.02 /30

Type

Active ingredient

UBLITUXIMAB-XIIY

FINGOLIMOD HYDROCHLORIDE

Manufacturer

Tg Therapeutics, Inc

Novartis

Dosage forms

Injectable

Capsule

Drug class

—

Sphingosine 1-Phosphate Receptor Modulator

Boxed warning

None

Half-life

—

about 6 to 9 days (average apparent terminal half-life)

Treats

Demyelinating Diseases, Chronic Progressive Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

Frequently asked questions

What is the difference between Briumvi and Gilenya?

Briumvi contains Ublituximab-Xiiy, while Gilenya contains Fingolimod Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.